Výsledky vyhledávání - "Helmerhorst, FM"

Levonorgestrel release rates over 5 years with the Liletta® 52-mg intrauterine system

Publikováno v: Contraception. 94:353-356

To understand the potential duration of action for Liletta®, we conducted this study to estimate levonorgestrel (LNG) release rates over approximately 5½years of product use.Clinical sites in the U.S. Phase 3 study of Liletta collected the LNG intr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ad2ce915bfccf0e93f7011d906b6172
https://doi.org/10.1016/j.contraception.2016.04.010

Zobrazit plný text záznamu

Venous Thrombosis, Oral Contraceptives and High Factor VIII Levels

Autor: F.R. Rosendaal, Helmerhorst Fm, Kitty W.M. Bloemenkamp, Jan P. Vandenbroucke

Publikováno v: Thrombosis and Haemostasis. 82:1024-1027

SummaryRecently, it has been described that elevated plasma levels of factor VIII are a strong risk factor for venous thrombosis. We analysed the data of the Leiden Thrombophilia Study, a population based case-control study on the causes of venous th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::84404754ac289f73ad41d3b230b67a5f
https://doi.org/10.1055/s-0037-1614323

Zobrazit plný text záznamu

Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen

Autor: H. R. Büller, Helmerhorst Fm, K. W. M. Bloemenkamp, Jan P. Vandenbroucke, F.R. Rosendaal

Publikováno v: Lancet, 346(8990), 1593-1596. Elsevier Limited

Recent concern about the safety of combined oral contraceptives (OCs) with third-generation progestagens prompted an examination of data from a population-based case-control study (Leiden Thrombophilia Study). We compared the risk of deep-vein thromb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe93761f26ba49ccc5ac9cf6e65fa507
https://doi.org/10.1016/s0140-6736(95)91929-5

Zobrazit plný text záznamu

Plný text ve formátu HTML

Treatment of valvular heart disease during pregnancy for improving maternal and neonatal outcome

Autor: Henriquez, DDCA, Roos - Hesselink, Jolien, Schalij, MJ, Klautz, RJM, Helmerhorst, FM, de Groot, CJM

Publikováno v: Cochrane Database Systematics Review. John Wiley & Sons Ltd.
ISSUE=5;ISSN=1469-493X;TITLE=Cochrane Database Systematics Review

Background Valvular heart disease constitutes the majority of all causes of heart disease in pregnancy. In the presence of valvular heart disease, the necessary haemodynamic changes of pregnancy might cause heart failure, leading to severe maternal a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::b5ba30bfb9458251371ab427ab0c59ea
https://pure.eur.nl/en/publications/2ab237b7-6513-4698-b6ad-2c84e6a882e3

Zobrazit plný text záznamu

The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study

Autor: Helmerhorst Fm, Jan P. Vandenbroucke, Frits R. Rosendaal, A. van Hylckama Vlieg, Catharina Jacoba Maria Doggen

Publikováno v: The BMJ
BMJ (Clinical Research Edition), 339(132). British Medical Association

Objective To assess the thrombotic risk associated with oral contraceptive use with a focus on dose of oestrogen and type of progestogen of oral contraceptives available in the Netherlands. Design Population based case-control study. Setting Six part

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51b54ffab0c8f06e68975670856a329f
http://europepmc.org/articles/PMC2726929

Zobrazit plný text záznamu

Comparison of ovarian stimulation regimens for in vitro fertilization (IVF) with and without a gonadotropin-releasing hormone (GnRH) agonist: Results of a randomized study

Autor: A B van de-Helder, Helmerhorst Fm, C Waegemaekers, Naaktgeboren N, Blankhart A, R Brand

Publikováno v: Journal of In Vitro Fertilization and Embryo Transfer. 7:358-362

In order to diminish the cancellation rate due to a premature endogeneous LH surge and/or to a poor ovarian response and thus increasing the pregnancy rate, a GnRH agonist (Buserelin) was applied in patients starting their first ovarian stimulation w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d32bdc5c7bc578b3dfdd3ba3f96d2f8
https://doi.org/10.1007/bf01130591

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání